UPClytics
EnglishDeutsch
Sign inSign up
View all cases

UPC APP 43786/2024

Jul 26, 2024·EP3167888 +1 more: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Case details
Status
Written Phase
Action
Generic
Category
Costs Assessments
Parties
Claimants
Reps: Elena Hennecke (Freshfields)
Respondents
Reps: Andrea Ritter (Simmons & Simmons)
Division
Hamburg LD
Judges
Technology
Organic Chemistry
Language
English
First decided
Aug 1, 2025
Decisions
  • 2025-08-01
    Costs onlyCostsGeneric application

    Hamburg Local Division (1 August 2025) issued a costs decision following the dismissal of Alexion Pharmaceuticals' provisional measures application against Samsung Bioepis. The court assessed Samsung Bioepis' recoverable litigation costs, disallowing the costs of two UK solicitors as disproportionate but allowing the costs of the private expert Prof. Kontermann and reasonable travel expenses.

    Legal issues:Cost decision (R. 151 RoP)Reasonable and proportionate legal costsExpert costsUK solicitor costs disallowed
Documents
Document titleDatePublic
action.phaseChange.caseClose2026-05-07Not public
Receipt2026-01-06Not public
Cover sheet2026-01-06Not public
Other document Defendant2026-01-06Not public
action.communication.general2025-12-03Not public
Headnote-and-Keywords2025-08-01Not public
Outcome of the Order2025-08-01Not public
Order with grounds2025-08-01Public
Order with grounds2025-08-01Not public
Receipt2025-07-23Not public
Exhibit S_S 052025-07-23Not public
Exhibit_S_S_012025-07-23Not public
20240726 SB12 UPC Alexion v SB EP888 - request for cost recovery_Redacted2025-07-23Not public
20250723_Alexion_vs_SB12_Request_for_Confidentiality_R_262.2_App_43786_20252025-07-23Not public
Exhibit_S_S_032025-07-23Not public
Receipt2025-07-23Not public
Exhibit_S_S_102025-07-23Not public
20250723_Alexion_vs_SB12_Request_for_Confidentiality_R_262.2_App_16372_20252025-07-23Not public
Exhibit_S_S_092025-07-23Not public
20250404_Further_Reply_to_Comment_re_cost_decision_EP888_redacted_version2025-07-23Not public
Exhibit FBD-C 12025-07-14Not public
Comments2025-07-14Not public
Anhoerung2025-07-02Not public
Receipt2025-04-04Not public
Exhibit_S_S_092025-04-04Not public
20250404_Alexion_vs_SB12_Further_Reply_to_Comment_re_cost_decision_EP8882025-04-04Not public
Exhibit_S_S_102025-04-04Not public
Comments2024-09-09Not public
Written Submission2024-09-03Not public
anhoerung kosten2024-08-12Not public
Receipt2024-07-26Not public
Exhibit S&S 12024-07-26Not public
Exhibit S&S 62024-07-26Not public
Exhibit S&S 22024-07-26Not public
Exhibit S&S 82024-07-26Not public
Exhibit S&S 32024-07-26Not public
Exhibit S&S 72024-07-26Not public
Exhibit S&S 52024-07-26Not public
Application for a Cost Decision2024-07-26Not public
Exhibit S&S 42024-07-26Not public
Samsung Bioepis NL B.V. v Alexion Pharmaceuticals, Inc. — UPC APP 43786/2024 | UPClytics